1 / 60

Myelodysplastic Syndromes: An Update

Myelodysplastic Syndromes: An Update. Thuy Le, MD Texas Cancer Associates Internal Medicine Grand Round April 19, 2006. HF. 80 yo male: OSA, gout, CAD, and prostate cancer who was referred for progressive anemia.

bat
Télécharger la présentation

Myelodysplastic Syndromes: An Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Myelodysplastic Syndromes: An Update Thuy Le, MD Texas Cancer Associates Internal Medicine Grand Round April 19, 2006

  2. HF • 80 yo male: OSA, gout, CAD, and prostate cancer who was referred for progressive anemia. • Past few months: noticed his health started to decline. Localized prostate cancer: end of 2005, tx external beam radiation. • Prior to any radiation: wbc 4.1 Hg 9.5 Plt 193 and MCV of 102. • One month after radiation: Hg 8.6 and plt 138. Progressive weakness and DOE. No chest pain. No GIB. He received 2 units of prbcs while waiting for results of work-up.

  3. HF • A week later: shortness of breath, worsening DOE, and generalized weakness. • His hemoglobin dropped down to 8.2 from 10. • Admitted to the hospital: found to have a non-ST elevation myocardial infarction. • Underwent a cardiac catherization which showed a 3-vessel disease. • CABG was recommended. Path of the bone marrow biopsy showed MDS. • Question: Should this patient undergo a CABG?

  4. HF • PMH: OSA on CPAP; Gout • CAD: diagnosed 30 years ago; told to have blockage • Prostate cancer: diagnosed Dec 2005 undergoing radiation • Social: widow, 60 pack year, quit 30 years ago; occasional etoh; former lawyer • Meds: Lortab, Vytorin, Toprol XL, Digitek

  5. HF • Pex: appears tired, DOE from door to room • No LAD, no oral lesions • Chest: bilateral rales about ¼ up • CV: regular RR with 3/6 murmur • Abd: unremarkable • Ext: 1+ edema of LLE to knee • Neuro: non-focal, alert, oriented

  6. HF • Laboratory data: • Wbc 4.1 hg 8.9 hct 26.7 plt 158 mcv 103 ANC 3321 • Creatinine 1.2 Folate >24 Ferritin 222 B12 352 • Reticulocyte count 3.4 with an absolute of 84K • Serum erythropoeitin level 498

  7. Bone marrow biopsy • Cellularity: 70-75%, increased for patient’s age • Myeloid: adequate, immature cells/blasts not increased • Megakaryocytes: many atypical megakaryocytes noted; mononuclear forms and micromegakaryocytes • Erythroid precursors: dyspoietic changes are present in up to 10% of erythroid series • Flow cytometry: normal, blasts not increased • Cytogenetics: normal

  8. Hypercellular BM

  9. Mononuclear megakaryocyte

  10. Dyspoietic red cell precursors

  11. Introduction • MDS: disorders of hematopoietic stem cells • Characterized by dysplastic and ineffective blood cell production • Peripheral blood cytopenias • Variable risk of transformation to acute leukemia • Arise de novo or years after exposure to mutagenic therapy (radiation or chemotherapy)

  12. Background • MDS: first recognized in 1938 • 100 pts with refractory anemia without associated illness • 1976 French-American-British (FAB): defined RA with excess blasts (RAEB) and CMML as preleukemic states • 1982: added 3 more categories to this classification…adopted MDS • 2001 WHO classification

  13. French-American-British

  14. World Health Organization

  15. Incidence • De novo MDS: incidence not known • Exceeds the incidence of AML in the elderly • 10-15K cases per year in US • Risk increases with age • Per 100,000 • 0.5 for < age 50 • 5.3 for age 50-59 • 15 for age 60-69 • 49 for age 70-79 • 89 for age >80 • Median age: 65

  16. Clinical Presentation • Signs and symptoms are non-specific • Many asymptomatic • Routine laboratory screening • Others present with sxs from anemia • Fatigue, weakness, angina, dizziness • Infection, easy bruising, bleeding: less common • Fever and wt loss: uncommon

  17. Clinical presentation • Infection: while neutropenia is largely responsible for the high incidence of infection, granulocyte dysfunction may contribute • Bacterial infections predominate • Skin is most common • Infection: principal cause of death in pts with MDS • Fungal, viral, and mycobacterial infx can occur, rare without concurrent immunosuppressive agents

  18. Physical Exam • Hepatomegaly, splenomegaly, LAD: uncommon • Except CMML • Cutaneous manifestations: uncommon • Sweet’s syndrome( neutrophilic dermatosis): transformation to acute leukemia ( IL-6) • Granulocytic sarcoma (chloroma): herald disease transformation into acute leukemia

  19. Sweet’s syndrome

  20. Laboratory findings • Quantitative changes of one or more blood and bone marrow elements are the hallmark of the disease • Red cell series • Granulocytic series • Platelets • Bone marrow findings

  21. Red cell series • Anemia is almost uniformly present • Inappropriately low reticulocyte response • Anemia may be the only cytopenia or be accompanied by thrombocytopenia or neutropenia • Less than 5% present with an isolated neutropenia or thrombocytopenia in the absence of anemia

  22. Red cell series • Erythrocyte morphology: normocytic or macrocytic • Peripheral smear: basophilic stippling, Howell-Jolly bodies, and nucleated red cells • Ringed sideroblasts: iron granules occupy more than 1/3 of the nuclear rim

  23. Ringed sideroblasts

  24. Granulocytic series • Leukopenia: found in approximately 50% at time of diagnosis • Granulocytes: display reduced segmentation, aka pseudo-Pelger-Huet • Often with reduced or absent granulation

  25. Pseudo-Pelger-Huet

  26. Pseudo-Pelger Huet

  27. Platelets • Thrombocytopenia: varying degrees are present in ~25% of pts with MDS • Rarely represent an isolated early manifestation of the disease • Giant plts or circulating megakaryocyte fragments may be present • May have increased bleeding tendency despite adequate plt number

  28. Bone marrow alterations • BM: usually hypercellular • Accompanied by single or multilineage dysplasia • Hypercellular BM/pancytopenia: reflects premature cell loss via intramedullary cell death • Hypocellular: rare • See in therapy-related MDS • Megakaryocytes are normal or increased in number

  29. Auer rods • Within leukemic blasts • FAB: belongs to category of RAEB-T • WHO: its presence should lead to the suspicion that patient has already transformed into AML

  30. Auer Rods

  31. Diagnosis • Considered in any patient with unexplained cytopenia(s) • Nuclear hyposegmentation of granulocytes (Huet anomaly) • Mononuclear megakaryocytes, micromegakaryocytes, or megakaryocytes with dysplastic nuclei • Hypogranular neutrophils • Macrocytic or acanthocytic red blood cells • Ring sideroblasts in developing red cell precursors

  32. Differential diagnosis • Above findings not unique to MDS • Exclude other contributing conditions • Alcohol • Megaloblastic anemia • HIV • Medications • Heavy metals

  33. Differential diagnosis • Other causes of macrocytic anemia • B12 and folate deficiency • Megaloblastic anemia have high MCV, reduced retic count, and pancytopenia • Reduced neutrophil lobulation is characteristic of MDS • Combination of increased neutrophil lobulation and macrocytosis is pathognomonic of megaloblastic anemia

  34. Differential diagnosis • HIV: dysplastic hematopoiesis and variable degrees of cytopenia are common findings in HIV • Myelodysplasia was found up to 69% in BM of pts with HIV • Dysplasia can be reversible depending on the cause (meds vs infection) • Medications: associated with acquired dysplastic changes • Valproic acid, mycophenolate, gancyclovir, alemtuzumab • Reversible on reduction or discontinuation of medications

  35. Diagnosis • Need bone marrow biopsy, flow cytometry, immunochemical studies, and cytogenetics • Clonal chromosomal abnormality of 5q- and monosomy 7 confirms the dx of MDS • Deletion 5q

  36. Prognosis • FAB: less useful for determination of prognosis • International prognostic scoring system: 1997 • Take into account age, sex, clinical data, cytopenias, and cytogenetics

  37. IPSS

  38. Median Survival in MDS

  39. Treatment • Control of symptoms due to cytopenias • Improving quality of life, minimizing toxicity of therapy • Improving overall survival • Decreasing progression to AML

  40. National Comprehensive Cancer Network • Age, performance status, IPSS-defined risk category • Low intensity • Outpatient tx, hematopoietic factors, differentiation-inducing agents, low intensity chemotherapy • High intensity • Intensive combination chemotherapy and hematopoietic cell transplantation • May reduce risk of death from disease

  41. Who to Treat

  42. Hematopoietic cell transplantation • Very limited • donor availability, advanced age • Upper age limit for allogeneic HCT ~60 • 75% of pts with MDS >60 • Considered in pts <60, HLA-matched sibling donor, risk of disease progression, excellent PS • Transplant-related mortality and relapse rate at 5 years as high as 40% • Timing of transplantation: development of new cytogenetic abnormality, worsening cytopenia, progression to a higher IPSS group

  43. Chemotherapy • High dose • young • MDS with >10% blasts in BM

  44. Intermediate dose chemotherapy • Azacitidine: pyrimidine nucleoside analog of cytidine • Causes hypomethylation of DNA and direct cytotoxicity on abnormal BM hematopoietic cells • Median time to leukemia was 21 mos vs 13mos • Quality of life was significantly improved • No difference in overall survival • FDA: RA, RARS, RAEB and CMML

  45. Low dose chemotherapy • Immunomodulatory agents • Thalidomide • Lenalidomide • Thalidomide • Low response rate • Adverse side effects: fatigue, constipation, peripheral neuropathy, and drowsiness • Lenalidomide (Revlimid) • Thalidomide derivative without the neurologic toxicity • FDA approved 12/27/05: transfusion-dependent anemia due to low or intermediate-1 risk MDS associated with deletion 5q.

  46. 5q- syndrome • Karyotypic and clinical distinctiveness sets it apart from other subtypes • Female predominance (7:3) median age 68 at dx • Transfusion-dependent anemia 80% • Low incidence of neutropenia, thrombocytopenia, infection and bleeding • Low incidence of transformation into acute leukemia (16%) • May respond dramatically to lenalidomide

  47. Lenalidomide (Revlimid, CC-5013) • Efficacy of Lenalidomide in Myelodysplastic Syndromes. NEJ 352;6. Feb 2005 • Dose: 25mg or 10mg per day; or 10mg per day for 21/28 days • All pts had no response to recombinant erythropoietin or high epo level so low chance of responding • Results • 21/43 (49%) had either a >2g/dl increase in hg or became red cell transfusion independent • Restoration of normal karyocyte was noted in 10/20 pts • 9/12 pts with 5q- had restoration of normal karyocyte • Neutropenia and thrombocytopenia most common adverse events

  48. Hematopoietic growth factors • Recombinant human granulocyte colony-stimulating factor (GCSF) and recombinant human erythropoietin may be used • Decreased responsiveness commonly seen • Related to defective proliferation of hematopoietic precursors • Erythropoietin • Serum epo level: inversely related to the degree of anemia in pts with MDS • Level may be suboptimally elevated in MDS • Recombinant EPO : 20-40% with MDS respond • Responses more likely if serum EPO level <100mU/mL

  49. Hematopoietic growth factors • Response to EPO • May be delayed • One study of 281 pts with MDS: • 18% responded by 12 wks • 45% responded by 26wks • Predictors of response: RA, good karyotype, EPO <150

More Related